Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK8 | P45983 | 2/20 | 0.63 |
| ▸ | BTK | Q06187 | 2/20 | 0.63 |
| ▸ | MRGPRX2 | Q96LB1 | 2/20 | 0.63 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.63 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.58 |
| ▸ | HPGD | P15428 | 6/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.58 |
| ▸ | HTT | P42858 | 2/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.58 |
| ▸ | NPC1 | O15118 | 3/20 | 0.53 |
| ▸ | RAB9A | P51151 | 2/20 | 0.53 |
| ▸ | HTR1D | P28221 | 2/20 | 0.51 |
| ▸ | HTR3A | P46098 | 2/20 | 0.51 |
| ▸ | HTR6 | P50406 | 2/20 | 0.51 |
| ▸ | TMEM97 | Q5BJF2 | 2/20 | 0.51 |
| ▸ | HTR1A | P08908 | 1/20 | 0.51 |
| ▸ | DRD2 | P14416 | 1/20 | 0.51 |
| ▸ | HTR1B | P28222 | 1/20 | 0.51 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7061175 | 1.00 | MAPK8 (0.63) | MAPK8BTKMRGPRX2MAPK10KDM4E | |
| SCHEMBL7061171 | 1.00 | MAPK8 (0.63) | MAPK8BTKMRGPRX2MAPK10KDM4E | |
| SCHEMBL7269309 | 0.85 | KDM4E (0.63) | MAPK8BTKMRGPRX2MAPK10KDM4E | |
| SCHEMBL7066040 | 0.85 | KDM4E (0.63) | MAPK8BTKMRGPRX2MAPK10KDM4E | |
| SCHEMBL7061181 | 0.81 | NPC1 (0.64) | KDM4EHPGDALDH1A1HTTSMN1; SMN2 | |
| SCHEMBL7066787 | 0.79 | NPC1 (0.63) | KDM4EHPGDALDH1A1HTTSMN1; SMN2 | |
| SCHEMBL21775874 | 0.78 | KDM4E (0.78) | KDM4EHPGDALDH1A1HTTSMN1; SMN2 | |
| SCHEMBL7065621 | 0.75 | KDM4E (0.56) | KDM4EHPGDALDH1A1HTTSMN1; SMN2 | |
| SCHEMBL7063816 | 0.74 | KDM4E (0.57) | KDM4EHPGDALDH1A1HTTSMN1; SMN2 | |
| SCHEMBL7062668 | 0.70 | HPGD (0.65) | KDM4EHPGDALDH1A1HTTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6649759-B2 | Pyrazolo(1,5-a)pyrimidine derivatives; treating feeding, cardiovascular and psychological disorders | PFIZER INC. | 2003-11-18 | — | — | US | claimed |
| US-20030100546-A1 | Neuropeptide Y antagonists | ELLIOTT RICHARD L (US) | 2003-05-29 | — | — | US | claimed |
| US-20020061897-A1 | Neuropeptide Y antagonists | ELLIOTT RICHARD L (US) | 2002-05-23 | — | — | US | claimed |
| US-6649759-B2 | Pyrazolo(1,5-a)pyrimidine derivatives; treating feeding, cardiovascular and psychological disorders | PFIZER INC. | 2003-11-18 | — | — | US | disclosed |
| US-20030100546-A1 | Neuropeptide Y antagonists | ELLIOTT RICHARD L (US) | 2003-05-29 | — | — | US | disclosed |
| US-20020061897-A1 | Neuropeptide Y antagonists | ELLIOTT RICHARD L (US) | 2002-05-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030100546-A1 | Neuropeptide Y antagonists | NPY1R, NPY2R, GIPR | MAPK8 2765/4885BTK 3784/4885MRGPRX2 56/4885 |
| US-20020061897-A1 | Neuropeptide Y antagonists | NPY1R, NPY2R, GIPR | MAPK8 2765/4885BTK 3784/4885MRGPRX2 56/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.